Participant flow

Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer · Source last updated 2016-05-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   To determine the dose of mitoxantrone that can be safely administered with pentostatin, cyclosphosphamide, and rituximab in previously treated patient with CLL and other low grade B-cell malignancies.

   id

   FG000

   title

   Pentostatin,Cyclophosphamide,Rituximab & Mitoxantrone

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Deemed ineligible

   2. reasons

      1. group Id

         FG000

         num Subjects

         6

      type

      Adverse Event

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         50

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         43

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         7

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice